Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda (Q34359439)

1 August 2017

title

Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda (English)

1 reference

sulfamethoxazole/trimethoprim

1 August 2017

0 references

1 reference

0 references

1 reference

Damalie Nakanjako

0 references

Jonathan Mermin

1 reference

1 August 2017

John Lule

1 reference

1 August 2017

John Paul Ekwaru

1 reference

1 August 2017

Samuel Malamba

1 reference

1 August 2017

Robert Downing

1 reference

1 August 2017

Ray Ransom

1 reference

1 August 2017

Frank Kaharuza

1 reference

1 August 2017

David Culver

1 reference

1 August 2017

Francis Kizito

1 reference

1 August 2017

Rebecca Bunnell

1 reference

1 August 2017

Aminah Kigozi

1 reference

1 August 2017

Winnie Wafula

1 reference

1 August 2017

Robert Quick

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 October 2004

1 reference

1 August 2017

1 reference

inferred from page(s)

published in

The Lancet

1 reference

1 August 2017

volume

364

1 reference

1 August 2017

issue

9443

1 reference

1 August 2017

page(s)

1428-1434

1 reference

Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

Voluntary counselling, HIV testing and adjunctive cotrimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

Co-trimoxazole in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

Prophylactic use of cotrimoxazole against opportunistic infections in HIV-positive patients: Knowledge and practices of health care providers in Côte d'Ivoire

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

The Impact of Active Herpes Simplex Virus Infection on Human Immunodeficiency Virus Load

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

A study of HIV RNA viral load in AIDS patients with bacterial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

Changes in virus load markers during AIDS-associated opportunistic diseases in human immunodeficiency virus-infected persons

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

The efficiency of acute infection of CD4+ T cells is markedly enhanced in the setting of antigen-specific immune activation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

Plasmodium falciparum antigen-induced human immunodeficiency virus type 1 replication is mediated through induction of tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

Editorial response: do bacterial pneumonia and Pneumocystis carinii pneumonia accelerate progression of human immunodeficiency virus disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

Increased immune activation precedes the inflection point of CD4 T cells and the increased serum virus load in human immunodeficiency virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

Impact of opportunistic disease on survival in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

Impact of bacterial pneumonia and Pneumocystis carinii pneumonia on human immunodeficiency virus disease progression. Pulmonary Complications of HIV Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 Cell counts to chronic mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

Treatment of intestinal worms is associated with decreased HIV plasma viral load

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

Hormone replacement therapy and uterine leiomyomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

The efficacy of antimalarial monotherapies, sulphadoxine–pyrimethamine and amodiaquine in East Africa: implications for sub‐regional policy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

Resistance in vivo of Plasmodium falciparum to co-trimoxazole in western Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

Trimethoprim-sulfamethoxazole prophylaxis in sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

Adverse reactions to cotrimoxazole in HIV-infected patients: predictive factors and subsequent HIV disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2804%2917225-5

7 January 2021

10.1016/S0140-6736(04)17225-5

Identifiers

DOI

1 reference

1 August 2017

1 reference